CompletedNot Applicable

Cell Cycle Arrest Proteins for Early Diagnosis of Acute Kidney Injury After Solid Organ Transplant

Italy160 participantsStarted 2022-02-01

Plain-language summary

Renal failure is a common complication of lung transplant (LUTX) and orthotopic liver transplantation (OLTX). Early diagnosis of acute kidney injury (AKI) in this cohort is of utmost importance, since AKI after solid organ transplant is associated with worsened short and long-term outcomes. To now, early biomarkers of renal failure based on the measurement of cell-cycle arrest proteins have never been tested in this population.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Enlistment for bilateral LUTX * Enlistment for bilateral OLTX * Age \> 18 years * Signed informed consent Exclusion Criteria: * Age \< 18 years old * Urgency enlistment * Already undergone solid organ transplant * Preoperative use of RRT

What they're measuring

acute kidney injury

Timeframe: <7 days from transplant

Trial details

NCT IDNCT05907434

SponsorPoliclinico Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Acute Kidney Injury trials